Acyclovir Dosing Practices Across a Multicenter Cohort of Neonatal Intensive Care Units.

ABSTRACT:

Background

Acyclovir is the first-line therapy for neonatal herpes simplex virus infections. Therapy can mitigate morbidity and mortality but carries a risk for toxicity. We aimed to compare acyclovir dosing in neonatal intensive care units to published recommendations based on population pharmacokinetic (PopPK) analysis.

Methods

We performed a multicenter cohort study of infants in neonatal intensive care units managed by the Pediatrix Medical Group from 1997 to 2020. We included all infants who received acyclovir with complete dosing information. Our primary outcome was the proportion of courses with dosing within 80%-120% of the PopPK recommended daily dose and at the recommended dosing frequency. We compared dosing before and after the publication of the 2014 PopPK recom

SUBMITTER: Foote HP 

PROVIDER: S-EPMC11669730 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature